FDA keeps a firm grip on par­tial hold for trou­bled Re­pros Ther­a­peu­tics, with big tri­al de­mand

The news isn’t get­ting any bet­ter at Re­pros Ther­a­peu­tics $RPRX. Ear­ly Mon­day the Wood­lands, TX-based biotech put out the word that the par­tial hold placed on the Proellex pro­gram will re­main in place af­ter reg­u­la­tors made clear that the biotech will need to as­sem­ble a “large” safe­ty data­base on the drug ahead of any ap­proval. And that re­port sent its al­ready tat­tered shares in­to a fresh tail­spin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.